Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated:  4/30/2012
Dana-Farber Cancer Instiute
mi
from
Boston, MA
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
A Phase I Study of Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
Status: Enrolling
Updated: 4/30/2012
Dana-Farber Cancer Instiute
mi
from
Boston, MA
Click here to add this to my saved trials
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated:  5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated: 5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma
Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy
Status: Enrolling
Updated:  5/17/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma
Multimodality Statistical Model of Early Response of High Grade Glioma to Radiation Therapy
Status: Enrolling
Updated: 5/17/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
Status: Archived
Updated:  6/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
Status: Archived
Updated: 6/28/2012
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
Status: Enrolling
Updated:  7/5/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
Status: Enrolling
Updated: 7/5/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma
Status: Enrolling
Updated:  9/7/2012
UT MD Anderson Cancer Center
mi
from
Houston, TX
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
Autologous Stem Cell Rescue With CD133+ Selected Hematopoietic Progenitor Cells in Patients With High-Risk Neuroblastoma
Status: Enrolling
Updated: 9/7/2012
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas
Status: Enrolling
Updated:  9/27/2012
Clinical Research Facility
mi
from
New York, NY
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
A Phase 1 Dose-Escalation Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Subjects With Malignant Gliomas
Status: Enrolling
Updated: 9/27/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated:  10/3/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated: 10/3/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
A Phase II Single Arm Trial of Palonesetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma Patients Receiving Irinotecan in Combination With Bevacizumab
Status: Enrolling
Updated:  10/15/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
A Phase II Single Arm Trial of Palonesetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma Patients Receiving Irinotecan in Combination With Bevacizumab
Status: Enrolling
Updated: 10/15/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide
Status: Enrolling
Updated:  10/15/2012
The Preston Robert Tisch Brain Tumor Center at Duke
mi
from
Durham, NC
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide
Status: Enrolling
Updated: 10/15/2012
The Preston Robert Tisch Brain Tumor Center at Duke
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Cedars Sinai Medical Center Outpatient Cancer Ctr. (3)
mi
from
Los Angeles, CA
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Cedars Sinai Medical Center Outpatient Cancer Ctr. (3)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Dana Farber Cancer Institute SC-2
mi
from
Boston, MA
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Dana Farber Cancer Institute SC-2
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Montefiore Medical Center MMC
mi
from
Bronx, NY
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Montefiore Medical Center MMC
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Carolina's Medical Center - Mecklenburg Medical Group Blumenthal Cancer Center
mi
from
Charlotte, NC
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Carolina's Medical Center - Mecklenburg Medical Group Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Oregon Health and Science University Knight Cancer Institute
mi
from
Portland, OR
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Oregon Health and Science University Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Fox Chase Cancer Center FCC
mi
from
Philadelphia, PA
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Fox Chase Cancer Center FCC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
MD Anderson Cancer Center/University of Texas UT MD Anderson Cancer Ctr
mi
from
Houston, TX
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
MD Anderson Cancer Center/University of Texas UT MD Anderson Cancer Ctr
mi
from
Houston, TX
Click here to add this to my saved trials
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Status: Enrolling
Updated:  10/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Status: Enrolling
Updated: 10/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
A Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Nuvigil® (Armodafinil) in Newly Diagnosed Malignant Glioma Patients Experiencing Fatigue Secondary to External Beam Radiation Therapy and Concurrent Temozolomide
Status: Enrolling
Updated:  11/1/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Nuvigil or Placebo in Newly Diagnosed Malignant Glioma
A Randomized, Double Blind, Placebo-Controlled Study Evaluating the Effect of Nuvigil® (Armodafinil) in Newly Diagnosed Malignant Glioma Patients Experiencing Fatigue Secondary to External Beam Radiation Therapy and Concurrent Temozolomide
Status: Enrolling
Updated: 11/1/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Immunotoxin, MR1-1
Phase I Study of Immunotoxin, MR1-1
Status: Enrolling
Updated:  12/12/2012
Duke University Health System
mi
from
Durham, NC
Study of Immunotoxin, MR1-1
Phase I Study of Immunotoxin, MR1-1
Status: Enrolling
Updated: 12/12/2012
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/18/2012
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/18/2012
Weill Cornell Medical College/New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  1/3/2013
Northwestern University
mi
from
Chicago, IL
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 1/3/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  1/3/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 1/3/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  1/3/2013
Massachusetts General Hospital
mi
from
Boston, MA
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 1/3/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  1/3/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 1/3/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated:  1/3/2013
University of Virginia, Department of Neurology
mi
from
Charlottesville, VA
LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma
Status: Enrolling
Updated: 1/3/2013
University of Virginia, Department of Neurology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  1/3/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 1/3/2013
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  1/3/2013
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 1/3/2013
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  1/3/2013
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 1/3/2013
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  1/3/2013
Cleveland Clinic
mi
from
Cleveland, OH
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 1/3/2013
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated:  1/3/2013
University of Virginia
mi
from
Charlottesville, VA
BIBF 1120 for Recurrent High-Grade Gliomas
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas
Status: Enrolling
Updated: 1/3/2013
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/17/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/17/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
Status: Enrolling
Updated:  2/8/2013
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
Status: Enrolling
Updated: 2/8/2013
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
Status: Enrolling
Updated:  2/8/2013
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
Status: Enrolling
Updated: 2/8/2013
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Characterization of Receptors in Non-functioning Pituitary Macroadenomas
Characterization of Receptors Present in Non-functioning Pituitary Macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR)
Status: Enrolling
Updated:  4/8/2013
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Characterization of Receptors in Non-functioning Pituitary Macroadenomas
Characterization of Receptors Present in Non-functioning Pituitary Macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR)
Status: Enrolling
Updated: 4/8/2013
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Constraint-Induced Movement Therapy in a Pediatric Oncology Population
Constraint Induced Movement Therapy in a Pediatric Oncology Population (SJCIT): A Pilot Study
Status: Enrolling
Updated:  4/9/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Constraint-Induced Movement Therapy in a Pediatric Oncology Population
Constraint Induced Movement Therapy in a Pediatric Oncology Population (SJCIT): A Pilot Study
Status: Enrolling
Updated: 4/9/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
Status: Enrolling
Updated:  4/11/2013
University of Florida
mi
from
Gainesville, FL
Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
Status: Enrolling
Updated: 4/11/2013
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
A Phase 1 Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)
Status: Enrolling
Updated:  5/8/2013
Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health
mi
from
Bethesda, MD
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
A Phase 1 Trial of Peptide-Based Glioma Vaccine IMA950 in Patients With Glioblastoma (GBM)
Status: Enrolling
Updated: 5/8/2013
Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health
mi
from
Bethesda, MD
Click here to add this to my saved trials
Short Course of Radiation for Gliomas in Elderly Patients
A Phase II Study of Hypofractionated Radiation With CyberKnife Stereotactic Radiosurgery Boost for High Grade Gliomas in Elderly Patients With Good Performance Status
Status: Enrolling
Updated:  5/10/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Short Course of Radiation for Gliomas in Elderly Patients
A Phase II Study of Hypofractionated Radiation With CyberKnife Stereotactic Radiosurgery Boost for High Grade Gliomas in Elderly Patients With Good Performance Status
Status: Enrolling
Updated: 5/10/2013
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Assessment of Eloquent Function in Brain Tumor Patients
Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors
Status: Enrolling
Updated:  5/31/2013
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Assessment of Eloquent Function in Brain Tumor Patients
Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors
Status: Enrolling
Updated: 5/31/2013
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Status: Enrolling
Updated:  6/4/2013
Saint Lukes Hospital
mi
from
Kansas City, MO
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Status: Enrolling
Updated: 6/4/2013
Saint Lukes Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma
Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma
Status: Enrolling
Updated:  6/12/2013
Oncology Service, Wills Eye Institute
mi
from
Philadelphia, PA
A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma
Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma
Status: Enrolling
Updated: 6/12/2013
Oncology Service, Wills Eye Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Capecitabine and Temozolomide for Neuroendocrine Cancers
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
Status: Enrolling
Updated:  7/1/2013
Columbia University Medical Center
mi
from
New York, NY
Capecitabine and Temozolomide for Neuroendocrine Cancers
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
Status: Enrolling
Updated: 7/1/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors
A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors
Status: Enrolling
Updated:  7/1/2013
Rockefeller University
mi
from
New York, NY
Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors
A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors
Status: Enrolling
Updated: 7/1/2013
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease
Status: Enrolling
Updated:  7/2/2013
Medical University of South Carolina
mi
from
Charleston, SC
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease
Status: Enrolling
Updated: 7/2/2013
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Status: Enrolling
Updated:  7/9/2013
University of Maryland School of Medicine
mi
from
Baltimore, MD
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
Status: Enrolling
Updated: 7/9/2013
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.
Status: Enrolling
Updated:  7/18/2013
The Emory Clinic
mi
from
Atlanta, GA
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.
Status: Enrolling
Updated: 7/18/2013
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.
Status: Enrolling
Updated:  7/18/2013
Emory University Hospital
mi
from
Atlanta, GA
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.
Status: Enrolling
Updated: 7/18/2013
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Neurosurgical Use of Interstitial Laser Therapy (ILT)
Neurosurgical Use of Interstitial Laser Therapy (ILT)
Status: Enrolling
Updated:  8/14/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Neurosurgical Use of Interstitial Laser Therapy (ILT)
Neurosurgical Use of Interstitial Laser Therapy (ILT)
Status: Enrolling
Updated: 8/14/2013
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Birmingham, AL
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials